Pharmaceutical - Diabetes, Neurological

Filter

Current filters:

DiabetesNeurological

Popular Filters

Bristol-Myers Squibb refocuses R&D strategy

Bristol-Myers Squibb refocuses R&D strategy

08-11-2013

US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued…

Anti-viralsBristol-Myers SquibbDiabetesManagementNeurologicalOncologyPharmaceuticalResearch

Three-fold risk of type 2 diabetes in children/youth taking antipsychotics, new study finds

22-08-2013

The increased prescribing of antipsychotics for children and youth has heightened concerns that this…

DiabetesNeurologicalPharmaceuticalResearch

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

GW Pharma posts six-month results; progresses cannabinoid pipeline including into diabetes and UC

05-06-2013

UK biopharma company GW Pharmaceuticals (AIM: GWP), which is developing and commercializing novel therapeutics…

DiabetesFinancialGastro-intestinalsGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Mylan settles with Shionogi and Andrx over Fortamet; Merck & Co diagnostics deal with Luminex

14-03-2013

US generic drugmaker Mylan (Nasdaq: MYL) has entered into a settlement agreement with Japan's Shionogi…

AndrxDiabetesFortametGenericsLuminexMerck & CoMylan LaboratoriesNeurologicalNorth AmericaPatentsPharmaceuticalShionogi

Anti-aging breakthrough could mean new drugs within five years

09-03-2013

Drugs that combat aging may be available within five years, following landmark work led by an Australian…

DiabetesGlaxoSmithKlineNeurologicalOncologyPharmaceuticalResearchresveratrol

Pfizer's Quillivant XR oral suspension now available in USA; GlaxoSmithKline files BLA for albiglutide

15-01-2013

Confirming expectations announced when Pfizer (NYSE: PFE) revealed its $680 million acquisition of NextWave…

albiglutideDiabetesGlaxoSmithKlineMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalQuillivantRegulation

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Research shows diabetes drug rosiglitazone improves memory

21-11-2012

Rosiglitazone, the active ingredient of GlaxoSmithKline's diabetes drug Avandia, has shown promise as…

AvandiaDiabetesGlaxoSmithKlineNeurologicalPharmaceuticalResearchrosiglitazone

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development

14-11-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg

09-11-2012

US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's…

DegludecDiabetesMerck & CoNeurologicalNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegsuvorexantTresiba

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada

02-11-2012

US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

Shire's Dermagraft cleared in Canada; settles Intuniv litigation

06-09-2012

Ireland headquartered Shire (LSE: SHP), NASDAQ: SHPG) says that its lead regenerative medicine product,…

Anchen PharmaceuticalsDermagraftDermatologicalsDiabetesGenericsIntunivNeurologicalNorth AmericaPatentsPharmaceuticalRegulationShireTWi Pharmaceuticals

Diabetes drug metformin makes brain cells grow

08-07-2012

The widely used diabetes drug metformin comes with a rather unexpected and alluring side effect: it encourages…

DiabetesNeurologicalPharmaceuticalResearch

Sanofi's Aubagio reduces MS relapse; firm aims to build diabetes portfolio

01-06-2012

Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) today reported top-line results from…

AubagioBiotechnologyDiabetesGenzymeMergers & AcquisitionsNeurologicalPharmaceuticalResearchSanofiteriflunomide

Diabetes drug shows promise for traumatic brain injury

30-05-2012

Although the death toll is relatively low for people who suffer from traumatic brain injury (TBI), it…

Diabetesexendin-4NeurologicalPharmaceuticalResearch

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy

18-05-2012

Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan

22-12-2011

Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization…

Asia-PacificBiotie TherapiesDegludecDiabetesEuropeLundbeckNeurologicalNovo NordiskPharmaceuticalRegulationSelincro

Mochida diabetes deal with Merck; Vanda links with Megapharm

14-12-2011

Japanese mid-sized drugmaker Mochida Pharmaceutical (TYO: 4534) saw its shares jump 5.8% to 900 yen,…

BiotechnologyDiabetesFanaptLicensingMegapharmMerck & CoMochida PharmaceuticalNeurologicalPharmaceuticalVanda Pharmaceuticals

Prior CHMP positive benefit-risk for pioglitazone confirmed; EMA starts NSAIDS review

24-10-2011

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has clarified its…

ActosDiabetesEuropeNeurologicalPharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Marina Biotech’s intranasal insulin delivery formulations for sale

27-09-2011

A patent portfolio related to rapid-acting intranasal (IN) insulin delivery formulations, which is owned…

DiabetesLicensingMarina BiotechNeurologicalPatentsPharmaceuticalResearch

Back to top